Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
Abstract Introduction Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient. Methods We summarized the efficacy and s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7064 |
| _version_ | 1827320450508652544 |
|---|---|
| author | Yi Li Jiang Juan Mu Rui Cui Xin Li Jia Wang Qing Li Jingyi Li Nan Mou Qi Deng |
| author_facet | Yi Li Jiang Juan Mu Rui Cui Xin Li Jia Wang Qing Li Jingyi Li Nan Mou Qi Deng |
| author_sort | Yi Li Jiang |
| collection | DOAJ |
| description | Abstract Introduction Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient. Methods We summarized the efficacy and side effects of anti‐CD19 CAR T‐cell therapy in 12 patients with R/R GI lymphoma. Based on literature, the R/R GI lymphoma patients were divided into subgroups with different characteristics: Bulky/No bulky disease, Gastric/Gastrointestinal involvement, Gastrointestinal/Combined extra‐gastrointestinal lesions, Ulcer/Lumps or nodules type, With/without gastrointestinal bleeding. Results The objective response rate (ORR) was 66.67% in these 12 patients. The ORR was 83.33% in no bulky disease group, 80.00% in gastric involvement group, 100.00% in ulcer type group, and 80.00% in no gastrointestinal bleeding group. The CR rate was 33.33% in these 12 patients. The CR was 50.0% in no bulky disease group, 60.00% in gastric involvement group, and 80.00% in ulcer type group. The PFS and OS rate of the 12 patients at 6 months after infusion were 54.55% and 58.33%, respectively. The overall survival (OS) at 6 months was higher in no bulky disease group. There was no difference of the OS or the progression free survival (PFS) at 6 months between the other groups. The mean peak of CAR‐T cells and Cytokine Release Syndrome (CRS) grade were higher in gastrointestinal lesions group. The mean peak of IFN‐γ and CRS grade were higher in gastrointestinal bleeding group. Four out of six patients in group of gastrointestinal lesions group were patient with high tumor burden. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding. Conclusions The ORR and CR of high tumor load, gastrointestinal involvement, lumps or nodules type and gastrointestinal bleeding group were lower. The CRS grade was higher in gastrointestinal lesions group and in gastrointestinal bleeding group. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding. |
| first_indexed | 2024-04-25T00:45:17Z |
| format | Article |
| id | doaj.art-9535177f35744ea48bd4af32d7204110 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-25T00:45:17Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-9535177f35744ea48bd4af32d72041102024-03-12T04:52:34ZengWileyCancer Medicine2045-76342024-02-01134n/an/a10.1002/cam4.7064Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphomaYi Li Jiang0Juan Mu1Rui Cui2Xin Li3Jia Wang4Qing Li5Jingyi Li6Nan Mou7Qi Deng8Department of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaShanghai Genbase Biotechnology Co., Ltd Shanghai ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine Nankai University Tianjin ChinaAbstract Introduction Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient. Methods We summarized the efficacy and side effects of anti‐CD19 CAR T‐cell therapy in 12 patients with R/R GI lymphoma. Based on literature, the R/R GI lymphoma patients were divided into subgroups with different characteristics: Bulky/No bulky disease, Gastric/Gastrointestinal involvement, Gastrointestinal/Combined extra‐gastrointestinal lesions, Ulcer/Lumps or nodules type, With/without gastrointestinal bleeding. Results The objective response rate (ORR) was 66.67% in these 12 patients. The ORR was 83.33% in no bulky disease group, 80.00% in gastric involvement group, 100.00% in ulcer type group, and 80.00% in no gastrointestinal bleeding group. The CR rate was 33.33% in these 12 patients. The CR was 50.0% in no bulky disease group, 60.00% in gastric involvement group, and 80.00% in ulcer type group. The PFS and OS rate of the 12 patients at 6 months after infusion were 54.55% and 58.33%, respectively. The overall survival (OS) at 6 months was higher in no bulky disease group. There was no difference of the OS or the progression free survival (PFS) at 6 months between the other groups. The mean peak of CAR‐T cells and Cytokine Release Syndrome (CRS) grade were higher in gastrointestinal lesions group. The mean peak of IFN‐γ and CRS grade were higher in gastrointestinal bleeding group. Four out of six patients in group of gastrointestinal lesions group were patient with high tumor burden. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding. Conclusions The ORR and CR of high tumor load, gastrointestinal involvement, lumps or nodules type and gastrointestinal bleeding group were lower. The CRS grade was higher in gastrointestinal lesions group and in gastrointestinal bleeding group. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding.https://doi.org/10.1002/cam4.7064B‐cell lymphomachimeric antigen receptor (CAR)gastrointestinal lymphomarelapsed/refractory |
| spellingShingle | Yi Li Jiang Juan Mu Rui Cui Xin Li Jia Wang Qing Li Jingyi Li Nan Mou Qi Deng Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma Cancer Medicine B‐cell lymphoma chimeric antigen receptor (CAR) gastrointestinal lymphoma relapsed/refractory |
| title | Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma |
| title_full | Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma |
| title_fullStr | Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma |
| title_full_unstemmed | Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma |
| title_short | Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma |
| title_sort | efficacy and side effects of anti cd19 car t cell therapy in patients with relapsed refractory gastrointestinal lymphoma |
| topic | B‐cell lymphoma chimeric antigen receptor (CAR) gastrointestinal lymphoma relapsed/refractory |
| url | https://doi.org/10.1002/cam4.7064 |
| work_keys_str_mv | AT yilijiang efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT juanmu efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT ruicui efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT xinli efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT jiawang efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT qingli efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT jingyili efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT nanmou efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma AT qideng efficacyandsideeffectsofanticd19cartcelltherapyinpatientswithrelapsedrefractorygastrointestinallymphoma |